John Gandolfo
electroCoreAbout John P. Gandolfo
Independent director since April 2020; age 64 in 2025. Former CFO with 30+ years of financial leadership at public and private healthcare companies, retired in 2024 as CFO of Eyenovia. Recognized by the Board as an Audit Committee financial expert; B.A. in Business Administration from Rutgers University. Tenure on ECOR’s Board: April 2020–present.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Eyenovia, Inc. | Chief Financial Officer | 2018–2024 (retired 2024 ) | Led finance at public biopharma; cash flow optimization |
| Xtant Medical Holdings, Inc. | Chief Financial Officer | 2010–2017 | Finance leadership across multi-site medtech operations |
| Progenitor Cell Therapy LLC | Chief Financial Officer | Not disclosed | CFO role in cell therapy operations |
| Power Medical Interventions | Chief Financial Officer | Not disclosed | CFO role; medtech sector |
| Bioject, Inc. | Chief Financial Officer | Not disclosed | CFO role; medical technology |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Oragenics, Inc. | Director | Since Sep 2023 | Development-stage pharma; board service |
| Odyssey Health, Inc. | Director | Since 2019 | Medtech; audit committee service mentioned |
Board Governance
- Independence: ECOR Board determined all directors other than the CEO are independent under SEC and Nasdaq rules; Gandolfo is independent.
- Committee assignments (2024–2025): Audit Committee member; Compensation Committee Chair; not on Nominating & Governance.
- Audit Committee financial expertise: Board deems Gandolfo an “audit committee financial expert.”
- Attendance and engagement: Board met 7 times in 2024; each director attended ≥75% of Board and committee meetings; non-management directors held executive sessions at regularly scheduled meetings.
| Committee | 2024 Membership | Chair | Meetings (2024) |
|---|---|---|---|
| Audit | Gandolfo (member) | Patton | 6 |
| Compensation | Gandolfo (member) | Gandolfo | 5 |
| Nominating & Governance | Not listed for Gandolfo | Errico | 5 |
Fixed Compensation
- ECOR’s Non-Employee Director Cash Retainers (effective Oct 1, 2023): Board $50,000; Audit Chair $20,000; Compensation Chair $15,000; Nominating Chair $10,000; Committee member retainers: Audit $10,000; Compensation $7,500; Nominating $5,000. Paid quarterly.
- Gandolfo’s cash fees: $75,000 in 2024 (consistent with Board retainer + Audit member + Compensation Chair).
| Year | Board Cash Retainer (Policy) | Committee Member/Chair (Policy) | Gandolfo Cash Fees |
|---|---|---|---|
| 2023 | $50,000 (effective 10/1/23) | Audit member $10,000; Comp chair $15,000; Nom chair $10,000 | $55,834 |
| 2024 | $50,000 | Audit member $10,000; Comp chair $15,000 | $75,000 |
Performance Compensation
- Annual equity grants to non-employee directors vest in 12 equal monthly installments until the next annual meeting; accelerate upon change of control per the 2018 Plan.
- Gandolfo equity awards: RSU/DSU grants in 2023 and 2024; no options reported for Gandolfo in 2024.
| Grant Year | Grant Date | Instrument | Shares/Units | Grant-Date Fair Value | Vesting |
|---|---|---|---|---|---|
| 2023 | 8/4/2023 | RSUs/DSUs | 21,739 | $100,000 | 12 monthly; fully vested before next annual meeting; CoC acceleration |
| 2024 | 9/3/2024 | RSUs/DSUs | 16,583 | $102,400 | 12 monthly; fully vested before next annual meeting; CoC acceleration |
No explicit performance metrics tied to director equity (e.g., TSR or EBITDA hurdles) are disclosed; director equity is time-based.
Other Directorships & Interlocks
- Compensation committee interlocks: ECOR discloses no interlocks or insider participation on its compensation committee.
- Related-party capital raises: Directors participated in ECOR private placements in Aug 2023 and May–Jun 2024; Gandolfo is not listed among purchasers.
Expertise & Qualifications
- Financial leadership and expense/cash flow optimization across healthcare companies; extensive CFO experience.
- Audit committee financial expert designation.
- Education: B.A. in Business Administration, Rutgers University.
Equity Ownership
- Beneficial ownership (as of July 10, 2025): 69,087 shares; comprises 4,066 common shares and 65,021 deferred stock units; less than 1% of outstanding shares.
- Prior year (as of June 15, 2024): 50,704 shares; comprises 2,266 common shares and 48,438 deferred stock units; less than 1% of outstanding shares.
- Hedging policy: ECOR prohibits director/officer hedging of company securities.
| Date (Record) | Total Beneficial Ownership | Common Shares | Deferred/Restricted Units | % of Shares Outstanding |
|---|---|---|---|---|
| Jun 15, 2024 | 50,704 | 2,266 | 48,438 | <1% (per filing) |
| Jul 10, 2025 | 69,087 | 4,066 | 65,021 | <1% (per filing) |
Insider trades: Attempted to fetch Form 4 activity via insider-trades skill for “Gandolfo” at ECOR (2024–2025), but the endpoint returned 401 Unauthorized; no Form 4 data retrieved. We can re-run upon access restoration.
Governance Assessment
- Strengths: Independent status; chairs Compensation Committee; recognized audit financial expert; adequate meeting attendance; no disclosed related-party transactions involving Gandolfo; board’s move to declassify (subject to shareholder approval) is investor-aligned.
- Alignment: Holds RSU/DSU-based director equity and common shares; participates in standard director compensation structure; ECOR prohibits hedging, which supports alignment.
- Risks/RED FLAGS: None disclosed specific to Gandolfo. No interlocks, no related-party exposure, no pledging disclosed; not a purchaser in insider-affiliated financings.
Monitoring: If declassification is approved, committee leadership continuity and annual director elections increase accountability. Continue tracking Compensation Committee decisions (no outside consultant engaged in 2023–2024), and any future related-party financings for potential conflicts.